CHF Solutions Ships Aquadex SmartFlow Products to Florida for Use with COVID-19 Patients
CHF Solutions (NASDAQ: CHFS) has successfully sold Aquadex SmartFlow consoles and disposables to a Central Florida hospital for treating COVID-19 patients. This ultrafiltration system is vital for managing fluid overload in critically ill patients, reducing severe complications like ARDS. The portable Aquadex device enhances fluid balance management, especially when dialysis resources are limited. CEO John Erb highlights the growing demand for this therapy across hospitals as they strive to effectively treat patients impacted by the pandemic.
- Successful sale of Aquadex SmartFlow systems to a hospital, indicating strong market demand.
- Aquadex therapy provides critical support for managing fluid overload in COVID-19 patients.
- Increased adoption of ultrafiltration therapy across multiple hospitals enhances market presence.
- None.
EDEN PRAIRIE, Minn., June 11, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced that it has sold Aquadex SmartFlow™ consoles and disposables to a critical care hospital for use in the treatment of COVID-19 patients in Central Florida.
Managing fluid balance in critically ill COVID-19 patients is important to avoid potentially life-threatening complications, such as volume overload, acute respiratory distress syndrome (ARDS), and other conditions related to progressive congestion. Because of this need, several hospitals across the country have included a simplified ultrafiltration system, such as Aquadex therapy, into their treatment protocol for fluid management for COVID-19 patients, especially when dialysis equipment and staff are limited. As recently cited, isolated ultrafiltration is an optimal strategy that primarily focuses on fluid extraction and optimization of volume status.1 The Aquadex SmartFlow system, a portable ultrafiltration device with small extracorporeal volume (i.e. 35 ml), provides a predictable method for fluid extraction, making it more likely to achieve precise fluid balance in these patients.
“Hospitals continue to see the need for ultrafiltration to treat patients affected with COVID-19 throughout the country,” said John Erb, CEO of CHF Solutions. “The Aquadex SmartFlow system provides a simple, predictable and smart solution and we are pleased that the therapy is being used to help patients in Central Florida.”
1 https://pubmed.ncbi.nlm.nih.gov/32336959/
About CHF Solutions
CHF Solutions, Inc. (CHFS) is a medical device company dedicated to changing the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow system for ultrafiltration therapy. CHF Solutions is headquartered in Minneapolis, Minn., with wholly-owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.
About the Aquadex SmartFlow System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the use of the Aquadex system to treat patients affected with COVID-19. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACTS INVESTORS: Claudia Napal Drayton Chief Financial Officer, CHF Solutions, Inc. 952-345-4205 MEDIA: Jessica Stebing Health+Commerce 260-336-6202
FAQ
What is the significance of the sale of Aquadex SmartFlow systems by CHF Solutions?
How does the Aquadex SmartFlow system help COVID-19 patients?
When did CHF Solutions announce the sale of Aquadex systems?
What is the stock symbol for CHF Solutions?
